Publications, Pharmaceutical

Why it is time to think differently about Nasal delivery of Biologics

COVID-19 has reinvigorated interest in the advantages of nasal delivery for a pharmaceutical industry already embracing a shift towards biologics.

This article considers the challenges and potential benefits of combining the two. The nasal delivery of biologics offers considerable potential for both local and systemic action and for direct access to the brain and CNS to address currently unmet therapeutic need. The unique features of biologics are discussed with reference to the associated difficulties of nasal delivery and the benefits of partnership with experts such as Aptar Pharma is highlighted. Work on the development of vaccines and prophylactics for COVID-19 illustrates what is achievable.

Download Publication
Author(s): Gemma Budd Irene Rossi
4 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

12 May 2020

Drug Delivery Systems & Services for Lifecycle Management of Crisis Medications ...

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
1 May 2020

Supporting Improved Patient Onboarding and Adherence with Training Solutions

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
21 Apr 2020

Using in vitro dissolution tests for local bioequivalence in OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights

Read More
1 Apr 2020

Demonstrating bioequivalence in generic orally inhaled drug products

Publications, Pharmaceutical, Innovation & Insights

Read More
1 … 20 21 22 23 24 25

How Can We Help?

Back To Top